| P2093 | author name string | Esther Lutgens | |
| | Christine D Dijkstra | |
| | Gijs Kooij | |
| | Koos J F van Dorst | |
| | Suzanne A B M Aarts | |
| | Tom T P Seijkens | |
| P2860 | cites work | Platelet-derived CD40L: the switch-hitting player of cardiovascular disease | Q74627856 |
| | A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory | Q74813297 |
| | Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide | Q77377234 |
| | IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions | Q77963029 |
| | A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology | Q81441210 |
| | Drug discovery. Magnificent obsession | Q81538257 |
| | Short communication: impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases | Q81554199 |
| | Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis | Q81575313 |
| | Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay | Q82225806 |
| | CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation | Q82310803 |
| | Targeting and liposomal drug delivery to CD40L expressing T cells for treatment of autoimmune diseases | Q87049259 |
| | Relationship between metalloproteinase 2 and 9 concentrations and soluble CD154 expression in Iranian patients with multiple sclerosis | Q87722024 |
| | Investigation of gene-gene interactions between CD40 and CD40L in Polish multiple sclerosis patients | Q88044438 |
| | Defining the clinical course of multiple sclerosis: the 2013 revisions | Q22241654 |
| | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| | Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L | Q24297472 |
| | CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis | Q26772339 |
| | B Cells and Autoantibodies in Multiple Sclerosis | Q26801386 |
| | Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain | Q29614225 |
| | Follicular helper CD4 T cells (TFH) | Q29615063 |
| | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 |
| | Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation | Q30573013 |
| | Revised diagnostic criteria of multiple sclerosis | Q30733519 |
| | Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. | Q30849102 |
| | Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future | Q33601679 |
| | Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile | Q33656103 |
| | Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis | Q33835268 |
| | CD40 is expressed and functional on neuronal cells | Q34085854 |
| | Immune function of microglia | Q34094707 |
| | Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12 | Q34145393 |
| | Requirement of transmembrane domain for CD154 association to lipid rafts and subsequent biological events | Q34384705 |
| | The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation | Q34548189 |
| | Association of SNPs of CD40 gene with multiple sclerosis in Russians | Q34683951 |
| | Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis | Q34787127 |
| | Dynamics of B cells in germinal centres | Q35446555 |
| | Discovery of small molecule CD40-TRAF6 inhibitors | Q35549406 |
| | The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function | Q35661793 |
| | CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis | Q35747327 |
| | Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand | Q35957193 |
| | IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). | Q46716712 |
| | CD40 is a major regulator of dendrite growth from developing excitatory and inhibitory neurons | Q47127227 |
| | FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies | Q47231815 |
| | Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. | Q47757443 |
| | Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. | Q47857770 |
| | Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. | Q47870376 |
| | Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). | Q47877434 |
| | Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder | Q47933799 |
| | Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis | Q47997496 |
| | Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. | Q48168687 |
| | CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium | Q48415768 |
| | Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation | Q48431300 |
| | Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). | Q48494762 |
| | Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. | Q48607199 |
| | Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. | Q48892230 |
| | Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis | Q48913563 |
| | CD40-mediated activation of T cells accelerates, but is not required for, encephalitogenic potential of myelin basic protein-recognizing T cells in a model of progressive experimental autoimmune encephalomyelitis | Q49025682 |
| | Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis. | Q50098900 |
| | Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. | Q51035537 |
| | Anti-CD40 Ab- or 8-oxo-dG-enhanced Treg cells reduce development of experimental autoimmune encephalomyelitis via down-regulating migration and activation of mast cells. | Q51037202 |
| | Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis. | Q53099338 |
| | Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS) | Q56901155 |
| | Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis | Q56907039 |
| | The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis | Q57667575 |
| | CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism | Q63354517 |
| | Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 |
| | Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment | Q73590337 |
| | Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis | Q73694665 |
| | Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis | Q74081274 |
| | Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses | Q74388332 |
| | Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses | Q74570628 |
| | Neuropathobiology of multiple sclerosis | Q36015091 |
| | IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. | Q36259695 |
| | Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells | Q36278572 |
| | The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. | Q36369234 |
| | CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis | Q36375941 |
| | Multiple sclerosis--the plaque and its pathogenesis | Q36410882 |
| | Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis | Q36484443 |
| | Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status | Q36722852 |
| | Janus faces of microglia in multiple sclerosis. | Q36769132 |
| | CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. | Q37061386 |
| | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis | Q37322100 |
| | CD40 and autoimmunity: the dark side of a great activator. | Q37365433 |
| | Molecular mechanism and function of CD40/CD40L engagement in the immune system. | Q37474929 |
| | The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. | Q37555464 |
| | Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance | Q37599837 |
| | CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics | Q37645910 |
| | CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 |
| | Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. | Q37995305 |
| | Will the real multiple sclerosis please stand up? | Q38020092 |
| | CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications | Q38042321 |
| | Role of the innate and adaptive immune responses in the course of multiple sclerosis | Q38384621 |
| | Regulatory B Cells and Mechanisms | Q38385328 |
| | Relapse in multiple sclerosis. | Q38420493 |
| | Natalizumab Changes The Peripheral Profile Of The Th17 Panel In Ms Patients: New Mechanisms Of Action | Q38637557 |
| | Disease-modifying therapies and infectious risks in multiple sclerosis | Q38760860 |
| | B cells and antibodies in progressive multiple sclerosis: Contribution to neurodegeneration and progression. | Q38891480 |
| | Safety concerns and risk management of multiple sclerosis therapies | Q39021781 |
| | Multiple Sclerosis: Immunopathology and Treatment Update | Q39420793 |
| | Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages | Q40708938 |
| | Following direct CD40 activation, human primary microglial cells produce IL-12 p40 but not bioactive IL-12 p70. | Q40805826 |
| | Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate | Q40926618 |
| | Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. | Q41732226 |
| | The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells | Q41739600 |
| | Tolerogenic dendritic cells produced by lentiviral-mediated CD40- and interleukin-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing T helper type 17 cells | Q42245452 |
| | Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice | Q42721429 |
| | A new clinically relevant approach to expand myelin specific T cells. | Q42805391 |
| | Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis | Q44003334 |
| | Activity profile in multiple sclerosis: an integrative approach. A preliminary report | Q44093006 |
| | CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation | Q45883525 |
| | CD40L controls obesity-associated vascular inflammation, oxidative stress and endothelial dysfunction in mice - translational aspects for man. | Q46284193 |
| P921 | main subject | experimental autoimmune encephalomyelitis | Q494066 |
| P304 | page(s) | 1791 | |
| P577 | publication date | 2017-12-12 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis | |
| P478 | volume | 8 | |